Ionis Q2 2021 Earnings Report
Key Takeaways
Ionis Pharmaceuticals reported $126 million in total revenues for Q2 2021. The company is on track to achieve its 2021 revenue guidance of more than $600 million. Key milestones included the completion of dosing in the tofersen Phase 3 VALOR study and full enrollment in the eplontersen Phase 3 NEURO-TTRansform study.
Total revenues reached $126 million.
Operating expenses were $199 million on a GAAP basis.
Net loss was $81 million on a GAAP basis.
Cash and investments totaled $2.1 billion at the end of the quarter.
Ionis
Ionis
Ionis Revenue by Segment
Forward Guidance
Ionis expects to achieve its 2021 revenue guidance of more than $600 million and anticipates increased R&D revenue in the second half of the year. The company is revising its 2021 operating expense and net loss guidance due to the license of Bicycle’s technology.
Revenue & Expenses
Visualization of income flow from segment revenue to net income